HOUSE 6227118th CongressReferred to the Subcommittee on Health.
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
- Last Action
- 11/10/2023
Actions
- 2023-11-10Referred to the Subcommittee on Health.
- 2023-11-03Referred to the House Committee on Energy and Commerce.
- 2023-11-03Introduced in House
- 2023-11-03Introduced in House
CRS Summary
As of 2023-11-03 (00)
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Cosponsors (20)
- Kevin McCarthy (R-CA)
- Michael Burgess (R-TX)
- Keith Self (R-TX)
- Juan Ciscomani (R-AZ)
- Kelly Armstrong (R-ND)
- Ruben Gallego (D-AZ)
- Yadira Caraveo (D-CO)
- Jim Costa (D-CA)
- Raúl Grijalva (D-AZ)
- Michelle Steel (R-CA)
- Mike Levin (D-CA)
- Monica De La Cruz (R-TX)
- David Valadao (R-CA)
- Debbie Lesko (R-AZ)
- Eric Swalwell (D-CA)
- Doug LaMalfa (R-CA)
- Brittany Pettersen (D-CO)
- Melanie Stansbury (D-NM)
- Jay Obernolte (R-CA)
- Scott Peters (D-CA)
Subjects
- Cardiovascular and respiratory health
- Drug safety, medical device, and laboratory regulation
- Health promotion and preventive care
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.